Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2003
11/06/2003US20030208048 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
11/06/2003US20030208045 Binds to Osteoclastogenesis Inhibitory Factor (OCIF) binding molecule (OBM)
11/06/2003US20030207836 Ovo nucleotide immuno-stimulant. The VAF contains one or more DNA constructs, each having a DNA molecule and a vector. Each of the DNA molecule contains one or more genes or gene fragments, each encoding an antigenic peptide of an avian
11/06/2003US20030207835 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
11/06/2003US20030207801 Novel polypeptides and nucleic acids encoding same
11/06/2003US20030207796 Specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an alpha 2-6 linkage are able to inhibit the conversion of human Factor X
11/06/2003US20030207793 Secreted alpha-helical protein - 32
11/06/2003US20030207447 Used to distinguish between arterial endothelial cells (arteries) and venous endothelial cells (veins)
11/06/2003US20030207446 Infectious papillomavirus pseudoviral particles
11/06/2003US20030207336 Method of treatment using humanized anti-cd11a antibodies
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207316 Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
11/06/2003US20030207299 Involves nucleic acid and amino acid sequences of human kinases; used in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders
11/06/2003US20030207293 Cryptic-like secreted protein
11/06/2003US20030207287 Non-stochastic generation of genetic vaccines
11/06/2003US20030207262 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
11/06/2003US20030206974 Antiviral substances from plant cuticular and epicuticular material
11/06/2003US20030206927 Methods for isolating and using fungal hemolysins
11/06/2003US20030206926 Characterized by the loss of its capability to reproductively replicate in human cell lines.
11/06/2003US20030206925 Isolated, recombinantly-generated, negative-sense, single-stranded RNA viruses having one or more mutations and/or deletions which reduce repression normally caused by V protein
11/06/2003US20030206924 Equine herpesvirus vaccine
11/06/2003US20030206922 Siderophore receptor polypeptides (SRPs) and porins from gram negative microbes and no greater than 10.0 endotoxin units per milliliter lipopolysaccharide; or SRPs isolated from a gram positive microbe; treating infectious diseases in cattle
11/06/2003US20030206921 Chlamydia antigens and corresponding DNA fragments and uses thereof
11/06/2003US20030206920 Proteinic product, process for its preparation, compositions containing it and use in medicaments
11/06/2003US20030206919 Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
11/06/2003US20030206917 Transferring a protein to a cell by coating the cell surface with a lipidated protein; and contacting said cell with a fusion protein having affinity for said lipidated protein and capable of binding to a cell surface receptor
11/06/2003US20030206916 Immunogenic peptides
11/06/2003US20030206914 Synthetic antigens for CD1-restricted immune responses
11/06/2003US20030206911 Modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target
11/06/2003US20030206910 Poloxamer 188, Poloxamer 237, Poloxamer 338, Poloxamer 124, Poloxamer 401, Tetronic 904, Tetronic 908, Tetronic 1107 or Tetronic 90R4; especially for treating chronic hepatitis and cancer
11/06/2003US20030206909 Antibody that binds to loop 6 of human CXCR4, especially a single chain antibody
11/06/2003US20030206908 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
11/06/2003US20030206907 Coadministering an antibody specific for one or more of the antigenic determinants characteristic of said vaccine
11/06/2003US20030206906 Water, a plasminogen activator, and a bacteriostatic organic alcohol preservative; does not contain a chelating agent; removal of fibrin-bound blood clots from a catheter
11/06/2003US20030206905 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
11/06/2003US20030206904 Method and therapeutic compositions for the treatment of myocardial infarction
11/06/2003US20030206903 Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/06/2003US20030206900 Vectors derived from antibodies for transferring substances into cells
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206890 Insect cells utilized that may be transformed with an expression system and thus proteins may be introduced into the composition through direct protein expression by the cells.
11/06/2003US20030206886 Neutralization of immune suppressive factors for the immunotherapy of cancer
11/06/2003US20030206885 Vaccine immunotherapy for immune suppressed patients
11/06/2003CA2827114A1 Multi plasmid system for the production of influenza virus
11/06/2003CA2483980A1 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
11/06/2003CA2483819A1 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
11/06/2003CA2483729A1 Method for treating anxiety and mood disorders in older subjects
11/06/2003CA2483564A1 Chimeric camp factors for vaccination against streptococcus infection
11/06/2003CA2483551A1 Immunogenic agent therapy using plasmapheresis or exchange transfusion
11/06/2003CA2483453A1 Combination vaccines including immunogenic gapc and camp factor polypeptides
11/06/2003CA2483007A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003CA2482996A1 Vitamin d3 upregulated protein 1 treats post-infarct myocardial ischemia
11/06/2003CA2482946A1 Multi plasmid system for the production of influenza virus
11/06/2003CA2482930A1 Epha2 antigen t epitopes
11/06/2003CA2480845A1 Adipocyte complement related protein zacrp8
11/05/2003EP1359221A2 HIV antisense proteins
11/05/2003EP1359156A2 Papilloma virus vaccine
11/05/2003EP1358910A1 Methods and means for prevention, inhibition and therapy of cancer
11/05/2003EP1358485A2 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
11/05/2003EP1358353A2 Identification of genetic determinants of polymorphic cyp3a5 expression
11/05/2003EP1358336A2 Human serine-threonine kinase
11/05/2003EP1358332A2 A serpin in bifidobacteria
11/05/2003EP1358331A2 Clostridium difficile vaccine
11/05/2003EP1358330A2 Transporters and ion channels
11/05/2003EP1358328A2 Regulation of human serotonin-like g protein-coupled recepter
11/05/2003EP1358327A2 Proteins and nucleic acids encoding same
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358319A2 Live influenza vaccine and method of manufacture
11/05/2003EP1358318A2 Hybridoma cell line g250 and its use for producing monoclonal antibodies
11/05/2003EP1358213A2 Humanized antibodies that recognize beta amyloid peptide
11/05/2003EP1358210A2 Adhesion molecules
11/05/2003EP1358172A2 Amino ceramide-like compounds and therapeutic methods of use
11/05/2003EP1357978A2 Hematopoietic stem cell gene therapy
11/05/2003EP1357944A2 Perylenequinones for use with immunotherapy agents
11/05/2003EP1357943A2 Methods and compositions for modulating the immune system of animals
11/05/2003EP1357942A2 Methods and compositions for treatment of immune dysfunction disorders
11/05/2003EP1357941A2 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
11/05/2003EP1357940A2 Hepatitis b virus treatment
11/05/2003EP1357939A2 Haemophilus influenza basb212 polynucleotides, polypeptides and use thereof
11/05/2003EP1357938A2 Hyperblebbing bacterial strains and use thereof for production of vaccines
11/05/2003EP1357937A2 Use of botuline toxin to obtain a product to be used in articular pathologies, particularly coxarthrosis, epicondylitis and rotator muscle cap pathology
11/05/2003EP1357930A2 Histidine-rich glycoprotein
11/05/2003EP1357919A1 Therapy-enhancing glucan
11/05/2003EP1357902A2 Therapeutic agents complexed with calcium phosphate and encased by casein
11/05/2003EP1357895A2 Vaccine composition and stabilisation method
11/05/2003EP0971703B9 Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration
11/05/2003EP0938506B1 Immunoglobulin superfamily domains and fragments with increased solubility
11/05/2003EP0912194B1 Polynucleotide vaccine formula, particularly for treating bovine respiratory disease
11/05/2003EP0863991B1 Antigenic preparations
11/05/2003EP0814835B1 Method for enhancing immunogenicity, product obtained and pharmaceutical composition
11/05/2003EP0489837B1 Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction
11/05/2003CN1454216A Antibodies to CCR5
11/05/2003CN1454215A Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
11/05/2003CN1454205A Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
11/05/2003CN1454091A Immunostimulatory nucleic acids
11/05/2003CN1454082A Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
11/05/2003CN1452984A Prepn of influenza-preventing antiserum
11/05/2003CN1126569C Low pathogenicity PRRS live virus vaccines and methods of preparation thereof
11/05/2003CN1126568C Adjuvant used in vaccine
11/04/2003US6642411 Compounds and compositions for delivering active agents
11/04/2003US6642371 Haemophilus adherence and penetration proteins
1 ... 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 ... 1823